HANSHOW
Hanshow, a global leader in developing and manufacturing electronic shelf labels (ESLs) and digital store solutions, proudly announces its recognition as a Sample Vendor in the Gartner Hype Cycle for Retail Technologies, 2024, under the Smart Shelf category, as well as in the Gartner Hype Cycle for Wireless Technology, 2024, under the Bluetooth ESL category. The Gartner Hype Cycle reports evaluate the maturity and adoption of various retail technologies, providing valuable insights for retail CIOs to make informed investment decisions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240807460853/en/
Hanshow‘s Holistic Green Store Solutions (Graphic: Business Wire)
According to the 2024 Hype Cycle for Retail Technologies report, “Smart shelves can provide critical real-time visibility to in-store, on-shelf availability; increase operational efficiency; guide customers and associates to discover products; and contribute inputs to Internet of Things (IoT)-based real-time store monitoring capabilities. Data from smart shelves can equip retailers to replicate a richer in-store experience, generating revenue uplift and delivering significant efficiency gains of store operations.”
Hanshow’s smart shelf technology and ESLs are positioned as high benefit innovations that are set to mature and gain widespread adoption within the next five to ten years. Hanshow’s smart shelf solutions integrate an advanced SaaS IoT management platform with devices such as ESLs and digital marketing to provide real-time inventory management, dynamic pricing, and customer engagement.
Hanshow was also recognized as a sample vendor in the 2024 Hype Cycle for Wireless Technologies under the Bluetooth ESL category. Bluetooth ESLs are highlighted by the report as a significant innovation - emerging technology with a high benefit rating and is expected to reach mainstream adoption within two to five years.
These capabilities significantly improve the efficiency of in-store operations and enhance the overall shopping experience and operational efficiency. ESLs are recognized for their ability to facilitate real-time, data-driven pricing and product information updates, crucial for retailers aiming to synchronize their digital and physical channels. Inclusion as a Sample Vendor in these Gartner Hype Cycle reports underscores Hanshow’s position as a leading innovator in the industry.
“We are honored to be recognized by Gartner as a Sample Vendor in the 2024 Hype Cycle for Retail Technologies and 2024 Hype Cycle for Wireless Technologies,” said Shiguo Hou, CEO of Hanshow. “This recognition validates our efforts in pioneering digital store solutions that help retailers optimize their operations, enhance customer engagement, and achieve sustainable growth.”
About Hanshow
Hanshow is a global leader in developing and manufacturing electronic shelf labels and digital store solutions. The company offers customers a series of customized IoT touchpoints and digital store solutions that deliver customer-centric insights. Hanshow's solutions have provided services to a vast number of stores in over 50 countries and regions, helping them streamline operations, optimize pricing strategies, and offer consumers a more personalized experience. Learn more: www.hanshow.com
Gartner Disclaimer:
Gartner, Hype Cycle for Retail Technologies, 2024, By Analysis Sandeep Unni, Max Panther Hammond, Published 29 July 2024
Gartner, Hype Cycle for Wireless Technologies, 2024, Analysis By Nick Jones, Published 5 August 2024
Gartner does not endorse any vendor, product, or service depicted in its research publications and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240807460853/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma19.10.2025 19:30:00 CEST | Press release
Data presented at ESMO 2025 show INCA33890, a TGFβR2×PD-1 bispecific antibody, has the potential to be an effective treatment in microsatellite stable (MSS) colorectal cancerPlanned initiation of registrational program for INCA33890 in MSS colorectal cancer in 2026Maturing data for INCB161734, a KRAS G12D inhibitor, shows a favorable safety profile and evidence of clinical benefit in heavily pre-treated pancreatic ductal adenocarcinoma (PDAC) patientsIncyte will expand on the results from the oral presentations at an in-person and webcasted event on Sunday, October 19, 2025, from 1:30 – 3:00 p.m. EDT (7:30 – 9:00 p.m. CEST) Incyte (Nasdaq:INCY) announced the first clinical data evaluating its TGFβR2×PD-1 bispecific antibody (INCA33890) for patients with microsatellite stable (MSS) colorectal cancer; and its potent, selective and orally bioavailable KRAS G12D inhibitor (INCB161734) for patients with KRAS G12D mutations, specifically pancreatic ductal adenocarcinoma (PDAC). The data were
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 11:15:00 CEST | Press release
New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection – including in people who progressed while on or after taking a PARP inhibitor, a patient population with particularly poor prognosis Corcept expands BELLA trial to three study arms: (i) platinum-resistant ovarian cancer, (ii) platinum-sensitive ovarian cancer and (iii) endometrial cancer Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom